HomeGeneticsConditionsGlutamate formiminotransferase deficiency
Back to Conditions
Glutamate formiminotransferase deficiency
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Conditions

Glutamate formiminotransferase deficiency

Glutamate formiminotransferase deficiency is a rare inherited disorder affecting development, with symptoms ranging from mild developmental delays to severe intellectual disabilities and megaloblastic anemia.

Overview

Glutamate formiminotransferase deficiency is a rare inherited disorder that can affect development.

In the past, researchers recognized a mild form and a severe form of glutamate formiminotransferase deficiency. Researchers have since found people who received a diagnosis of glutamate formiminotransferase deficiency as infants who do not appear to have any related health problems. Researchers are actively working to learn more about this condition.

Symptoms

The signs and symptoms associated with glutamate formiminotransferase deficiency have ranged from mild developmental delays with high urine levels of a molecule called formiminoglutamate (FIGLU) to more severe intellectual disabilities and megaloblastic anemia. Megaloblastic anemia occurs when a person has a low number of red blood cells (anemia) and the remaining red blood cells are larger than normal (megaloblastic).

Frequency

Glutamate formiminotransferase deficiency has an estimated incidence of between 1 in 46,000 people and 1 in 60,000 people, but fewer than 100 people with this condition have been reported in the medical literature. Individuals with the severe form of the disorder have all been of Japanese ancestry.

Causes

Variants (also called mutations) in the FTCD gene cause glutamate formiminotransferase deficiency. The FTCD gene provides instructions for making an enzyme that is involved in the breakdown of histidine, which is a building block (amino acid) of many different proteins. One of the enzyme's jobs is to convert FIGLU to a molecule called 5-formiminotetrahydrofolate.

The FTCD gene variants that cause glutamate formiminotransferase deficiency alter the function of the FTCD enzyme, which disrupts the enzyme’s ability to completely break down histidine. This can cause FIGLU to build up in the body and be released in the urine. It is unclear exactly how these changes are related to the specific health problems seen in some people with glutamate formiminotransferase deficiency.

Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell must have a variant to cause the disorder. The parents of an individual with an autosomal recessive condition each carry one copy of the altered gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition

  • Arakawa syndrome 1
  • FIGLU-uria
  • Formiminoglutamic acidemia
  • Formiminoglutamic aciduria
  • Formiminotransferase cyclodeaminase deficiency
  • Formiminotransferase deficiency
  • FTCD deficiency

Frequently Asked Questions

definitive diagnosis is made by sequencing the FTCD gene to identify pathogenic variants. In newborn screening, a urine test for elevated formiminoglutamate (FIGLU) can flag potential cases, prompting confirmatory genetic testing. Early detection—often within the first few months of life—allows for timely intervention, especially for those with severe forms.
Because the disorder disrupts histidine metabolism, a diet rich in folate and vitamin B12 can help mitigate anemia. Foods high in folate (leafy greens, legumes, fortified cereals) and B12 (meat, dairy, fortified plant milks) are recommended. In some cases, a doctor may prescribe folinic acid or B12 supplements, and a dietitian can tailor a meal plan that balances protein intake with the body’s altered metabolism.
Mild cases may show only subtle developmental delays, while severe cases can involve significant intellectual disability and anemia. Early interventions—such as speech and occupational therapy, individualized education plans, and regular hematology follow‑ups—can help children reach their potential. Monitoring growth, cognitive development, and blood counts every 3–6 months allows for timely adjustments to therapy.
Glutamate formiminotransferase deficiency is inherited in an autosomal recessive pattern. If both parents carry a pathogenic FTCD variant, there is a 25% chance with each pregnancy that the child will be affected. Prenatal options include chorionic villus sampling (CVS) or amniocentesis for targeted genetic testing, and pre‑implantation genetic diagnosis (PGD) can be considered if using in‑vitro fertilization. Genetic counseling is essential to discuss risks and testing strategies.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ